- Home
- KMDA vs EDD Comparison
KMDA vs EDD Comparison
Compare KMDA & EDD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KMDA
- EDD
- Stock Information
- Founded
- KMDA 1990
- EDD 2007
- Country
- KMDA Israel
- EDD United States
- Employees
- KMDA N/A
- EDD N/A
- Industry
- KMDA Biotechnology: Pharmaceutical Preparations
- EDD Finance Companies
- Sector
- KMDA Health Care
- EDD Finance
- Exchange
- KMDA Nasdaq
- EDD Nasdaq
- Market Cap
- KMDA 398.5M
- EDD 329.4M
- IPO Year
- KMDA N/A
- EDD N/A
- Fundamental
- Price
- KMDA $6.95
- EDD $5.35
- Analyst Decision
- KMDA Strong Buy
- EDD
- Analyst Count
- KMDA 2
- EDD 0
- Target Price
- KMDA $13.00
- EDD N/A
- AVG Volume (30 Days)
- KMDA 77.7K
- EDD 254.3K
- Earning Date
- KMDA 11-12-2025
- EDD 01-01-0001
- Dividend Yield
- KMDA 2.88%
- EDD 7.52%
- EPS Growth
- KMDA 27.97
- EDD N/A
- EPS
- KMDA 0.32
- EDD N/A
- Revenue
- KMDA $169,517,000.00
- EDD N/A
- Revenue This Year
- KMDA $14.49
- EDD N/A
- Revenue Next Year
- KMDA $10.12
- EDD N/A
- P/E Ratio
- KMDA $21.01
- EDD N/A
- Revenue Growth
- KMDA 9.67
- EDD N/A
- 52 Week Low
- KMDA $5.43
- EDD $4.22
- 52 Week High
- KMDA $9.16
- EDD $4.95
- Technical
- Relative Strength Index (RSI)
- KMDA 52.44
- EDD 50.82
- Support Level
- KMDA $6.72
- EDD $5.33
- Resistance Level
- KMDA $7.11
- EDD $5.40
- Average True Range (ATR)
- KMDA 0.19
- EDD 0.07
- MACD
- KMDA 0.03
- EDD 0.01
- Stochastic Oscillator
- KMDA 60.68
- EDD 82.14
About KMDA Kamada Ltd.
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.
About EDD Morgan Stanley Emerging Markets Domestic Debt Fund Inc.
Morgan Stanley Emerging Markets Domestic Debt Fund Inc is a closed-end management investment company. The company's primary investment objective is to seek a high level of current income, with a secondary investment objective of long-term capital appreciation. It seeks to achieve investment objectives by investing, under normal circumstances, at least 80% of its managed assets in emerging markets domestic debt. The fund's portfolio includes sovereign, quasi-sovereign, corporate bonds in emerging markets.